Compare Thomson Reuters Corp (TRI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Thomson Reuters Corp vs Zoetis Inc — how do they compare? Thomson Reuters Corp trades at $97 (market cap $42.12B), while Zoetis Inc trades at $73.65 (market cap $30.29B). The key difference: Thomson Reuters Corp is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| TRI | ZTS | |
|---|---|---|
Market Cap | $42.12B | $30.29B |
Sector | Industrials | Health |
52-Week High | $173.48 | $150.61 |
52-Week Low | $76.55 | $71.91 |
Enterprise Value | $44.73B | $37.86B |
Dividend Yield | 2.7% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Thomson Reuters (TRI) trades at $98.81, down 6.5% recently, amid a bearish technical signal. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $0.99 per share and revenue growth of 9% year-over-year. Recent news highlights AI expansion with the launch of its proprietary LLM 'Thomson' and a cybersecurity incident affecting its case management system. Valuation ratios include a P/E of 26.03 and net income margin of 21.22%, indicating robust profitability but premium pricing.
Outlook is mixed: analyst consensus is bullish with a $113 price target, but technical weakness and cybersecurity risks pose headwinds. Investment opportunity lies in TRI's recurring revenue model and AI-driven growth, while risks include execution challenges and market sentiment shifts. The stock's current dip may offer a entry point for long-term investors focused on sustainable tech adoption.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
